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Protease activity of plasma hemopexin.
Background. Previous studies into the relevance of a puta-
tive circulating factor in the pathogenesis of minimal change
nephrotic syndrome have opened the possibility that plasma
hemopexin might be an important effector molecule in this dis-
order. Thus, intra renal infusion of isolated plasma hemopexin
into rats induced minimal change like glomerular lesions and
proteinuria. Both, in vivo and in vitro effects of the active
isoform of hemopexin could be attributed to protease activ-
ity of this molecule. However, the question remained whether
hemopexin per se rather than some contaminating plasma fac-
tor is responsible for the potential enzymatic activity of this
molecule.
Methods Recombinant hemopexin was prepared according
to standard methods in Pichia pastoris and compared for its
identity and protease activity with plasma hemopexin using
Western blotting and various in vitro assays. Unilateral renal
perfusion in anesthetized rats was used to test the protein-
uria inducing capacity of recombinant hemopexin versus heat-
inactivated recombinant hemopexin.
Results. The blotting results show identical 85 kD bands in
both native as well as recombinant hemopexin. Incubation of
kidney tissue with recombinant hemopexin resulted in loss of
of glomerular ectoapyrase and sialoglycoproteins, as shown by
immunohistochemistry, which effect can be inhibited with the
serine protease inhibitor phenylmethanesulfonyl fluoride. Ar-
tificial substrates for serine proteases, like kallikrein or throm-
bin, are hydrolysed by recombinant hemopexin in vitro, and not
by heat-inactivated recombinant hemopexin or saline. Unilat-
eral kidney perfusion of recombinant hemopexin, in contrast
to control Pichia transfection products or heat-inactivated re-
combinant hemopexin, followed by a protein marker showed
significantly enhanced urinary protein leakage 5.0, 10.0, and
15.0 minutes after perfusion.
Conclusion. It is concluded that the hemopexin molecule as
such can potentially act as a toxic protease, leading in the rat to
proteinuria and glomerular alterations characteristic for mini-
mal change nephrotic syndrome.
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Plasma hemopexin is an acute-phase reactant which is
believed to act as a protective molecule against heme-
mediated oxidative injury [1, 2], as well as nitric oxide–
mediated toxicity [3].
Thus, free heme is covalently bound by hemopexin
with high affinity (kD < 1 pmol/L) [4], and the heme-
hemopexin complex is transported to the liver where it is
internalized by hepatocytes via receptor-mediated endo-
cytosis [5–7]. Except from plasma hemopexin synthesized
by hepatocytes, the molecule is also expressed in neurons
of human brain [8], in ganglia of the neural retina [8],
and hemopexin can also be induced in response to injury
in peripheral nerves [9, 10]. Recently we observed syn-
thesis of hempexin in cytokine-stimulated human mesan-
gial cells in vitro [11]. This wide distribution suggests that
hemopexin exerts its protective function at various sites
of the body.
Previously serine protease like activity was detected
in samples of hemopexin isolated from normal human
plasma [12, 13]. After incubation of plasma hemopexin
samples with human or rat kidney tissue, and subse-
quent washing and staining of the sections for glomerular
extracellular matrix molecules (ECMs) (i.e., sialoglyco-
proteins, ectoapyrase, or heparan sulfate proteoglycans)
resulted in a significant loss of these molecules. This effect
could be inhibited by serine protease inhibitors, but not
by broad-spectrum collagenase inhibitors, whereas heat
inactivation of the hemopexin preparation abolishes its
protease activity [14]. Interestingly intra renal infusion of
plasma hemopexin into rats resulted in minimal change–
like glomerular alterations concomitant with transient
proteinuria [13, 14].
The question remained however whether the putative
protease activity of hemopexin is due to either hemopexin
per se or to contaminating plasma proteases. Therefore
we now prepared and tested recombinant hemopexin, us-
ing over expression of the human hemopexin gene prod-
uct in Pichia pastoris.
In the present communication protease activity in re-
combinant hemopexin prepared by standard techniques
is reported. It is also shown that unilateral perfusion
of recombinant hemopexin into the rat kidney induces
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enhanced glomerular permeability for plasma proteins, as
was previously demonstrated for native hemopexin [14].
It is concluded that not contaminating plasma pro-
teases but the hemopexin molecule as such may exert
protease activity, which molecule is potentially able to
affect the glomerular filtration barrier.
METHODS
Purification of plasma hemopexin and production
of recombinant hemopexin
Human plasma hemopexin was prepared from normal
human pooled serum according to Hrkal et al [4] with
minor modifications as described previously [12].
The purified fractions were evaluated by sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting. For the production of re-
combinant hemopexin, total RNA was isolated from the
HEPG2 cell line using Trizol reagens (Invitrogen, Leek,
The Netherlands) Synthesis of cDNA was primed with
oligo(dT) using Maloney murine leukemia virus-reverse
transcription (MMLV-RT) and a buffer provided by the
manufacturer (Invitrogen). Primers covering the com-
plete coding region of hemopexin were selected from
the sequence present in the GenBank (accession number
BC 005395). The forward primer was constructed [62–77]
from the hemopexin gene sequence with an EcoRI site
directly flanking the ATG triplet which will function as
the translation start site (5′-GGTAGAATTCATGGCT
AGGGTACTGG-3′). The reversed primer was selected
directly upstream the stop codon (1411-1438) and con-
tained an Xbal restriction site downstream the coding re-
gion (5′-ATAGTCTAGATGAGTGCAGCCCAGGAG-
3′). The polymerase chain reaction (PCR) reaction was
performed with 1 U Taq-polymerase (Amersham Bio-
sciences, Roosendaal, The Netherlands) and the reaction
buffer provided by the manufacturer. The PCR program
consisted of 40 cycles with a denaturation step of 30 sec-
onds at 94◦C, an annealing step of 30 seconds at 60◦C,
and an extension step of 2 minutes at 72◦C. The first de-
naturing step lasted for 5 minutes and the final extension
step lasted for 60 minutes to ensure the complete syn-
thesis of the hemopexin coding sequence. The expected
size of the resulting PCR product is 1350 bp. The ob-
tained PCR product was ligated in the pCRII-TOPO
vector (Invitrogen, Leek, The Netherlands) and trans-
formed to TOP 10F′ Escherichia coli. Ten independent
colonies were screened for the presence of an insert of
the expected size of 1350 bp. A sequence analysis was
performed on part of the clones to confirm that the se-
quence cloned matched the hemopexin sequence.
Plasmid DNA was isolated from one of the clones con-
taining the proper insert. The hemopexin insert was iso-
lated after digestion with EcoRI and Xbal, and ligated
into the EcoRI-Xbal restriction sites of the pPICZaA
vector (Invitrogen). The obtained hemopexin/pPICZaA
construct was used for the transformation of P. pastoris
using protocols as provided by the manufacturer. Se-
quence analysis of the insert, called PIC-hemopexin was
performed to confirm the proper ligation and in frame
ligation of the hemopexin insert.
A nonhemopexin-related purified Pichia product (r-Pr
3), obtained after transfection of proteinase 3 into P. pas-
toris as described elsewhere [15] was used as control pro-
tein in Western blots as well as unilateral renal perfusion
experiments.
Transformation of P. pastoris
P. pastoris strain GS115 was transformed using elec-
troporation according to the user’s manual (Invitrogen).
Briefly, 80 lL of electrocompetent yeast cells were mixed
with 10 lg of linearized hemopexin vector in a 0.2 cm
gap width electroporation cuvette. Cells were pulsed at
1500 V, 25 lF, 200  using the GenePulser electro-
poration apparatus (Bio-Rad, Veenendaal, The Nether-
lands). Subsequently, cells were selected on plates with
100 lg/mL zeocin (Invitrogen) at 30◦C. After 2 to 3 days
colonies emerged that were used for further screening.
Large-scale induction of recombinant hemopexin
and protein extraction from transfected Pichia cells
A high-density culture of P. pastoris transformant
PIC-hemopexin was grown in buffered glycerol com-
plex medium (BGMY), prepared according to the
Invitrogen user’s manual with 100 lg/mL zeocin in an
incubator rotary shaker at 225 rpm at 30◦C overnight.
The cells were collected by centrifugation. Recombinant
hemopexin was induced by resuspending the yeast cells
20% of the original volume of buffered methanol com-
plex medium (BMMY), prepared as described in the In-
vitrogen user’s manual and continuing the incubation.
Aliquots of 1 mL were drawn at 1, 2, 3, 4, 5, and 6 days
post-induction. Every 24 hours the induction was main-
tained by addition of methanol to a final concentration of
0.5%. The cell density of every aliquot was determined
by measuring the absorbance at 600 nm. Cell pellets were
prepared by centrifugation and stored at −80◦C until fur-
ther use. The hempexin production proved to be optimal
at 3 days post-induction (data not shown).
For large-scale induction high-density cultures of PIC-
hemopexin were grown in 500 mL BMGY medium by in-
cubation in a rotary incubator shaker at 225 rpm at 30◦C
overnight. The cells were collected by centrifugation and
resuspended in 100 mL of BMMY induction medium in
a 1 L Erlenmeyer flask and the incubation was contin-
ued for a further 3 days, with addition of methanol ev-
ery 24 hours to a final concentration of 0.5%. Cells were
collected by centrifugation and the pellet was stored at
−80◦C until protein extraction.
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The cell lysis procedure was carried out according to
the Invitrogen user’s manual with minor modifications.
A part of the supernatant was purified by affinity chro-
matography as described previously [12].
Antihemopexin antibodies, gradient PAGE
and Western blotting
Rabbit antihemopexin IgG prepaired as described pre-
viously in our own laboratory [16] as well as commer-
cially obtained polyclonal antihemopexin IgG (Dako
A/S, Glostrup, Denmark) were used.
SDS-gradient PAGE runs were done with native
or recombinant hemopexin samples according to stan-
dard procedures. Blots were stained with either antihe-
mopexin antibodies or with Ponceaux-S (Amersham Bio-
sciences), for protein detection.
Histochemistry, immunoblotting, and quantification
of glomerular ECMs
Glomerular sialoglycoproteins or glomerular ec-
toapyrase were stained by the colloidal ion or by mon-
oclonal antiapyrase antibody, respectively, as described
previously [12]
Reaction product was quantified using computerized
image analysis as described previously [17]. For each incu-
bation experiment in vitro, five sections each containing
approximately 30 glomeruli were screened. The results
are expressed as arithmetic means ± standard deviations.
Amidolytic assay
To test the protease activity of hemopexin upon artifi-
cial substrates which are sensitive to serine proteases two
chromogenic substrates were used [i.e., H-D-Pro-Phe-
Arg-pNA.2 HCl (S2302 used in the assay for kallikrein),
and H-D-Phe-Pip-Arg-pNa.2HCl (S2238, used in the as-
say for thrombin)] (Chromogenix, Milano Italy). The as-
says were carried out according to the prescriptions of
the manufacturer with minor modifications.
Depending on the experiment either S2302 or S2238
was dissolved in aquadest and mixed with hemopexin [500
lg per mL phosphate-buffered saline (PBS), pH 7.4] to
a final volume of 100 lL (final substrate concentrations
0.4 mmol/L). At the start of the incubation (t = 0), and 5,
10, and 25 hours after incubation (at 37◦C) the extinction
was measured at 405 nm by spectrophotometry.
Experimental animals and alternate kidney
perfusion ex vivo
Female Wistar rats (Harlan, Zeist, The Netherlands)
weighing 180 to 200 g were used for renal perfusion exper-
iments. Before use rats were tested for the presence of uri-
nary protein and protein excretion (pyrogallol method)
of less than 3 mg/24 hours was considered normal. Exper-
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Fig. 1. Two stains. (A) Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) runs of purified and nonpurified proteins
from stable Pichia transfectants. Electrophoretric patterns of purified
(lane 1), and nonpurified Pichia proteins after gradient PAGE (lane 3); it
can be seen that the purified material from Pichia transfected with either
hemopexin (lane 1) or the control Pr 3 gene product (lane 2) stain neg-
ative, whereas the same nonpurified proteins from Pichia transfected
with hemepexin show several bands (lane 3). M is marker molecules. (B)
Western blots of purified Pichia products or plasma hemopexin stained
with polyclonal antihemopexin IgG. It can be seen that material from
Pichia transfected with hemopexin (lane 2) shows an identical band
of approximately 85 kD as compared with plasma hemopexin (lane
4). Heat-inactivated recombinant hemopexin shows an identical band
(lane 3). The Pr 3 Pichia product stains negative (lane 1).
imental protocols were approved by the Animal Care and
Use Committee of the University of Groningen (Gronin-
gen, The Netherlands).
Unilateral perfusion of rat kidneys was carried out
as described previously [13, 18] in animals, anesthetized
by halothane/O2/N2O. Perfusion was done with either
100 lg recombinant hemopexin, heat-inactivated recom-
binant hemopexin, or r-Pr 3 in 4.0 mL saline [flow rate
0.67 mL/min followed by 10.0 mL diluted rat serum
(10.0 mg/mL) flow rate 1.5 mL/min)]. Urine samples were
collected for protein measurement before perfusion as
well as 5, 10, and 15 minutes after perfusion. Animals
were terminated by bleeding under anesthesia at the
end of each experiment and kidneys were prepared for
immunohistochemistry.
RESULTS
Sequencing of the purified gene products isolated from
P. pastoris cultures producing either PIC-hemopexin or
Pr3 showed the expected sequence.
Nonpurified Pichia proteins after gradient PAGE are
shown in Figure 1A and Western blots of this mate-
rial after affinity chromatography using antihemopexin
IgG columns are shown in Figure 1B. It is clear from
Figure 1A that nonpurified material obtained from Pichia
cultures transfected with hemopexin (Fig. 1A, lane 3)
show various protein bands, Identical material purified
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Fig. 2. Loss of glomerular staining after contact of kidney tissue with hemopexin in vitro. Micrographs of representative glomeruli of rat cryostat
sections stained for either sialogycoproteins (A to D), or glomerular ectoapyrase (E to H), following incubation with either phosphate-buffered
saline (PBS) (A and E), plasma hemopexin (0.5 mg/mL PBS) (B and F), recombinant hemopexin in PBS (0.1mg/mL) (C and G), or recombinant
hemopexin supplemented with phenylmethylsulfonyl fluoride (PMSF) (2.5 mmol/L) (D and H). Clearly diminished reaction product in the the
glomerular tuft in (B) and (C) versus (A), as well as in (F) and (G) versus (E) can be seen, reflecting impairement of these glomerular ECMs by
native or recombinant hemopexin. It can be seen that PMSF is able to inhibit the activity of recombinant hemopexin significantly (D) and (H)
versus (C) and (F). (A to D) Colloidal iron staining. (E to H) Immunostaining with monoclonal antiapyrase antibody and peroxidase-conjugated
goat antimouse antibody as a second step (magnification ×480).
B
Fig. 5. (continued.)
by affinity chromatography stains negative (Fig. 1A, lane
1). Also purified control Pichia product (i.e., r-Pr 3)
stains negative (Fig. 1A lane 2) In the Western blot
(Fig. 1B) bands of 85 kD are exclusively seen in purified
fractions obtained from yeast cell cultures transfected
with the hemopexin gene (Fig. 1B, lane 2), whereas r-Pr
3–transfected cultures were negative after the same treat-
ment (Fig. 1B, lane 1). Lane 3, with heat-inactivated
recombinant hemopexin shows an identical band as com-
pared to lane 2, following staining with antihemopexin
antibody. For comparison in lane 4 a clear 85 kD band
present in purified plasma hemopexin is shown after
staining with the same antibody.
Incubation of cryostat kidney sections with either
hemopexin or recombinant hemopexin followed by wash-
ing and staining for sialoglycoproteins (Fig. 2, top panel)
showed loss of staining (Fig. 2B and C) as compared
with control sections incubated with PBS (Fig. 2A),
or with recombinant hemopexin supplemented with
phenylmethylsulfonyl fluoride (PMSF) (Fig. 2D). Also
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Fig. 3. Quantification of glomerular reaction product. Staining for
glomerular ECMs [i.e., sialoglycoproteins (B) or glomerular apyrase
(A), after in vitro incubation of kidney sections with phosphate-buffered
saline (PBS) (white bars), plasma hemopexin (Hx) (hatched bars), re-
combinant hemopexin (rHx) (black bars), or recombinant hemopexin
supplemented with phenylmethylsulfonyl fluoride (PMSF) (stippled
bars). Columns represent mean scores of reaction product in kid-
ney sections from control animals after incubation with the various
hemopexin samples in vitro (arithmetic means ± standard deviation).
A significant decrease of reaction product can be seen in sections af-
ter incubation with either hemopexin or recombinant hemopexin as
compared to incubation with PBS. No decrease of reaction product
is shown after incubation with recombinant hemopexin supplemented
with PMSF. ∗Versus PBS, P < 0.01 (Wilcoxon). NS is statistically not
significant.
reduced staining for glomerular ectoapyrase is observed
(Fig. 2, bottom panel) after incubation with either plasma
hemopexin or recombinant hemopexin (Fig. 2F and G), as
compared with control incubations with PBS or recombi-
nant hemopexin with PMSF (Fig. 2E and H, respectively).
These data are summarized in Figure 3. Again, it can
be seen that the reduced stainability for glomerular ec-
toapyrase (Fig. 3A) as well as for glomerular sialogy-
coproteins (Fig. 3B) due to hemopexin or recombinant
hemopexin can be prevented by the serine protease in-
hibitor PMSF.
The activity of active recombinant hemopexin or heat-
inactivated recombinant hemopexin upon artificial sub-
strates for thrombin (Fig. 4, right panel) or kallikrein
(Fig. 4, left panel) is depicted. It is shown that in
contrast to heat-inactivated recombinant hemopexin,
both chromogenic substrates are converted after contact
with recombinant hemopexin. Control incubations with
saline instead of recombinant hemopexin showed simi-
lar results as compared to heat-inactivated recombinant
hemopexin.
Figure 5A shows data of unilateral renal perfusion ex-
periments in anesthetized rats with either recombinant
hemopexin control agents (i.e., heat-inactivated recom-
binant hemopexin or the nonrelated Pichia product r-Pr 3
followed by diluted plasma proteins as marker molecules
for glomerular protein leakage.
The protein level in the urine before perfusion (t = 0)
does not differ significantly between the three groups of
animals (2.70 ± 1.16, 2.94 ± 0.60, and 3.4 ± 1.5). However,
significant differences in urinary protein can be observed
5.0, 10.0, or 15.0 minutes after perfusion with recom-
binant hemopexin versus heat-inactivated recombinant
hemopexin, or r-Pr 3 [6.23 ± 4.40 vs. 3.62 ± 2.70 (heat-
inactivated recombinant hemopexin) or 3.1 ± 2.8 (r-Pr 3);
36.13 ± 10.30 vs. 2.76 ± 1.17 (heat-inactivated recombi-
nant hemopexin) or 5.2 ± 3.1 (r-Pr 3); and 24.97 ± 2.90 vs.
3.93 ± 1.40 (heat-inactivated recombinant hemopexin) or
4.8 ± 2.1 (r-Pr 3) respectively] (Fig. 5A). Exclusively fol-
lowing perfusion of recombinant hemopexin decreased
anionic sites or glomerular ectoapyrase was observed, as
illustrated in Figure 5B.
DISCUSSION
The aim of the present study was to settle the ques-
tion whether hemopexin or an unknown plasma con-
stituent, (alone or possibly complexed with hemopexin)
is able to affect the glomerular filtration barrier. There-
fore, we first transfected the human hemopexin gene into
P. pastoris to generate recombinant hemopexin and we
subsequently compared both native hemopexin and re-
combinant hemopexin for their immunochemical and en-
zymatic properties.
The sequence of PIC-hemopexin appeared to be iden-
tical with hemopexin sequences published in the liter-
ature [19]. The gene product isolated from P. pastoris
as detected by Western blots using antihemopexin an-
tibodies shows a molecular weight of approximately
85 kD (Fig. 1B), whereas the gene product of P. pastoris
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Fig. 4. Enzymatic activity of recombinant hemopexin (rHx) versus heat-inactivated recombinant hemopxin using chromogenic substrates sensitive
for serine proteases. Substrate S2302 (for kallikrein) (left panel) and S2238 (for thrombin) (right panel) are used. It can be seen that recombinant
hemopexin is able to induce hydrolysis of both of these artificial substrates, in contrast to heat-inactivated recombinant hemopexin (HI rHx) or
saline (control).
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Fig. 5. Protein leakage after unilateral perfusion of recombinant
hemopexin into rat kidneys. (A) Columns represent mean protein
leakage (± standard deviation) following perfusion of rat kidneys
of anesthetized rats with either recombinant hemopexin () (N =
7), heat-inactivated recombinant hemopexin () (N = 6), or r-Pr 3
(hatched columns) (N = 6), followed by diluted rat plasma. It can
be seen that before perfusion (t = 0) no significant difference of
protein excretion occurs whereas after 5, 10, or 15 minutes signifi-
cant enhancement of protein excretion occurs exclusively following
recombinant hemopexin perfusion. P values (recombinant hemopexin
vs. heat-inactivated hemopexin) as indicated (Mann-Whitney). NS is
statistically not significant; bars represent standard deviation. (B) Mi-
crographs of glomeruli from three representative rats after unilateral
kidney perfusion (t = 15) of recombinant hemopexin (panels A and D),
heat-inactivated hemopexin (panels B and E) or r-Pr 3 (panels C and D),
stained for sialoglycoproteins (panels A to C) or glomerular ectoapyrase
(panels D to F), as described under Fig. 2. It can be seen that loss of
sialoglycoproteins or reduced expression of glomerular ectoapyrase ex-
clusively occurs after perfusion with recombinant hemopexin (magnifi-
cation ×480).
cells inserted with a nonhemopexin-related insert stained
negative. Due to the magnitude of glycosylation of the
molecule, the molecular mass of plasma hemopexin may
vary, but ranges usually from 80 to 85 kD [12]. From the
molecular weight observed in recombinant hemopexin, it
can be concluded that the glycosylation of this particular
protein in Pichia is appropriate.
With respect to the enzymatic activity of hemopexin it
is concluded that recombinant hemopexin exerts iden-
tical protease activity as compared to purified plasma
hemopexin (Figs. 2 to 4).
Thus both the affection of glomerular ectoapyrase and
sialoglycoprotein in vitro can be inhibited by the ser-
ine protease inhibitor PMSF (Fig. 3). As described for
plasma hemopexin previously [12] also other serine pro-
tease inhibitors like antithrombin III or the protease in-
hibitor a2-macroglobulin are able to inhibit recombinant
hemopexin activity. In contrast, broad-spectrum collage-
nase inhibitors are not able to inhibit the protease activity
of hemopexin [12], nor that of recombinant hemopexin
(data not shown).
In addition heat inactivation at 80◦C for 20 minutes is
able to inactivate the protease activity of both hemopexin
and recombinant hemopexin (Figs. 4 and 5).
Taken these data together, we concluded that the
identical enzymatic activity observed in both, plasma
hemopexin as well as in recombinant hemopexin, points
to a property of the hemopexin molecule per se.
From Figure 5A it can be seen that perfusion of re-
combinant hemopexin, in contrast to heat-inactivated
recombinant hemopexin or r-Pr 3, leads to glomeru-
lar leakage of plasma proteins in the ex vivo perfu-
sion model used. Similar as shown previously after
intrarenal infusion of plasma hemopexin in conscious
rats in vivo [13], the glomerular protein leakage after
recombinant hemopexin is transient and decreases after
10 minutes.The reason for this remains to be investigated
but relates probably to the limited time period of infu-
sion and/or to the relatively small amount of recombinant
hemopexin perfused. Kidneys from rats perfused with re-
combinant hemopexin showed loss of glomerular anionic
sites and ectoapyrase in contrast to kidneys perfused with
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control agents (Fig. 5B). This is in line with previous re-
sults obtained after perfusion of native hemopexin in vivo
[16]. Although this artificial model does not allow conclu-
sions about the kinetics of the protein leakage observed
after hemopexin perfusion, it is clear that hemopexin is
able to induce glomerular protein leakage in vivo as has
also been shown previously after plasma hemopexin in-
fusion using a more physiologic model [13].
Thus, since recombinant hemopexin is able to induce
minimal change like glomerular alterations together with
enhanced glomerular permeability, in an identical man-
ner as described for plasma hemopexin, it is concluded
that this molecule, at least in certain experimental con-
ditions, may occur as an enzymatic isoform, which is po-
tentially toxic for the glomerular filtration barrier.
The activity of circulating hemopexin in healthy indi-
viduals is unclear. It is conceivable that in the normal
condition a potentially toxic isoform of hemopexin is
present as an inactive molecule as is the case for many
other plasma serine proteases, like complement compo-
nents or coagulation factors. Such silent molecules, either
zymogens or protease molecules complexed with an in-
hibitor, can be activated after certain proinflammatory
stimuli. Even isolation procedures per se can stimulate
certain zymogens to their activated form.
With respect to the clinical situation in minimal
change nephrotic syndrome, the question has been raised
whether glomerular charge neutralization is due to a po-
tentially toxic factor for instance hempexin or rather
a result of proteinuria as such. From the present data
no definitive conclusions can be drawn. However, in
previous experiments using in vivo intrarenal infusion
of hemopexin in conscious rats with an intact circula-
tion, a significant urinary protein peak concomitant with
minimal change nephrotic syndrome–like glomerular al-
terations was seen exclusively after infusion of small
amounts of hemopexin [13]. Although the putative rel-
evance of hemopexin in minimal change nephrotic syn-
drome remains to be established, there are two recent in
vitro observations which support a role for hemopexin in
either causing or perpetuating enhanced glomerular per-
meability in minimal change nephrotic syndrome. Thus,
T-cell–associated cytokines like tumor necrosis factor-
a (TNF-a) are able to enhance hemopexin production
in mesangial cells in vitro in a corticosteroid-dependent
manner [11] and second in plasma from patients with min-
imal change nephrotic syndrome in relapse we found en-
hanced hempexin activity as compared with patients with
minimal change nephrotic syndrome in remission or with
proteinuric subjects with other forms of primary glomeru-
lopathy [in press].
Further experiments are in progress focusing on the
glomerular permeability increasing effect of hemopexin
versus inactivated hemopexin in vivo, and the presence of
the active isoform of hemopexin in the circulation of sub-
jects with minimal change nephrotic syndrome in relapse
versus remission.
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